nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.355	1	CiPCiCtD
Sunitinib—kidney cancer—thyroid cancer	0.175	1	CtDrD
Sunitinib—RET—thyroid cancer	0.108	1	CbGaD
Sunitinib—HIPK3—Sorafenib—thyroid cancer	0.0108	0.0451	CbGbCtD
Sunitinib—AXL—Vandetanib—thyroid cancer	0.0103	0.043	CbGbCtD
Sunitinib—IRAK4—Vandetanib—thyroid cancer	0.0103	0.043	CbGbCtD
Sunitinib—FYN—Vandetanib—thyroid cancer	0.0103	0.043	CbGbCtD
Sunitinib—TYRO3—Vandetanib—thyroid cancer	0.0103	0.043	CbGbCtD
Sunitinib—FLT4—Vandetanib—thyroid cancer	0.00862	0.0359	CbGbCtD
Sunitinib—PLK4—Vandetanib—thyroid cancer	0.00862	0.0359	CbGbCtD
Sunitinib—YES1—Vandetanib—thyroid cancer	0.00862	0.0359	CbGbCtD
Sunitinib—MAP4K5—Vandetanib—thyroid cancer	0.00862	0.0359	CbGbCtD
Sunitinib—SLK—Vandetanib—thyroid cancer	0.00862	0.0359	CbGbCtD
Sunitinib—FGR—Vandetanib—thyroid cancer	0.00745	0.0311	CbGbCtD
Sunitinib—FLT3—Vandetanib—thyroid cancer	0.00745	0.0311	CbGbCtD
Sunitinib—KDR—Vandetanib—thyroid cancer	0.00745	0.0311	CbGbCtD
Sunitinib—RET—Vandetanib—thyroid cancer	0.00745	0.0311	CbGbCtD
Sunitinib—EPHB6—Vandetanib—thyroid cancer	0.00658	0.0275	CbGbCtD
Sunitinib—BLK—Vandetanib—thyroid cancer	0.00658	0.0275	CbGbCtD
Sunitinib—FLT1—Sorafenib—thyroid cancer	0.00621	0.0259	CbGbCtD
Sunitinib—MAP3K7—Sorafenib—thyroid cancer	0.00621	0.0259	CbGbCtD
Sunitinib—AURKC—Sorafenib—thyroid cancer	0.00621	0.0259	CbGbCtD
Sunitinib—STK10—Vandetanib—thyroid cancer	0.00592	0.0247	CbGbCtD
Sunitinib—PDGFRB—Vandetanib—thyroid cancer	0.00538	0.0225	CbGbCtD
Sunitinib—MAP2K5—Vandetanib—thyroid cancer	0.00538	0.0225	CbGbCtD
Sunitinib—FGFR1—Sorafenib—thyroid cancer	0.00519	0.0217	CbGbCtD
Sunitinib—FLT4—Sorafenib—thyroid cancer	0.00519	0.0217	CbGbCtD
Sunitinib—MAP3K19—Vandetanib—thyroid cancer	0.00495	0.0206	CbGbCtD
Sunitinib—RET—Sorafenib—thyroid cancer	0.00449	0.0187	CbGbCtD
Sunitinib—KDR—Sorafenib—thyroid cancer	0.00449	0.0187	CbGbCtD
Sunitinib—FLT3—Sorafenib—thyroid cancer	0.00449	0.0187	CbGbCtD
Sunitinib—HIPK4—Sorafenib—thyroid cancer	0.00397	0.0165	CbGbCtD
Sunitinib—EPHB6—Sorafenib—thyroid cancer	0.00397	0.0165	CbGbCtD
Sunitinib—PDGFRA—Sorafenib—thyroid cancer	0.00357	0.0149	CbGbCtD
Sunitinib—KIT—Sorafenib—thyroid cancer	0.00357	0.0149	CbGbCtD
Sunitinib—STK10—Sorafenib—thyroid cancer	0.00357	0.0149	CbGbCtD
Sunitinib—CSF1R—Sorafenib—thyroid cancer	0.00357	0.0149	CbGbCtD
Sunitinib—MAP2K5—Sorafenib—thyroid cancer	0.00325	0.0135	CbGbCtD
Sunitinib—PDGFRB—Sorafenib—thyroid cancer	0.00325	0.0135	CbGbCtD
Sunitinib—MAP3K19—Sorafenib—thyroid cancer	0.00298	0.0124	CbGbCtD
Sunitinib—ABCC4—Sorafenib—thyroid cancer	0.00109	0.00457	CbGbCtD
Sunitinib—ABCG2—Vandetanib—thyroid cancer	0.000977	0.00407	CbGbCtD
Sunitinib—ABCC2—Sorafenib—thyroid cancer	0.000651	0.00272	CbGbCtD
Sunitinib—ABCG2—Sorafenib—thyroid cancer	0.000589	0.00246	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.000435	0.00181	CbGbCtD
Sunitinib—CYP3A7—Sorafenib—thyroid cancer	0.000435	0.00181	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—thyroid cancer	0.000395	0.00165	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—thyroid cancer	0.000357	0.00149	CbGbCtD
Sunitinib—CYP3A5—Sorafenib—thyroid cancer	0.000326	0.00136	CbGbCtD
Sunitinib—OXSR1—Afatinib—Vandetanib—thyroid cancer	0.000285	0.317	CbGdCrCtD
Sunitinib—ABCB1—Sorafenib—thyroid cancer	0.000212	0.000885	CbGbCtD
Sunitinib—CYP3A4—Vandetanib—thyroid cancer	0.000211	0.00088	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—thyroid cancer	0.000129	0.000537	CbGbCtD
Sunitinib—CYP3A4—Sorafenib—thyroid cancer	0.000127	0.00053	CbGbCtD
Sunitinib—FLT1—saliva-secreting gland—thyroid cancer	7.96e-05	0.00258	CbGeAlD
Sunitinib—STK39—head—thyroid cancer	7.94e-05	0.00257	CbGeAlD
Sunitinib—MAP4K1—thyroid gland—thyroid cancer	7.92e-05	0.00257	CbGeAlD
Sunitinib—EPHB6—saliva-secreting gland—thyroid cancer	7.87e-05	0.00255	CbGeAlD
Sunitinib—CSNK2A1—head—thyroid cancer	7.84e-05	0.00254	CbGeAlD
Sunitinib—CSNK1E—trachea—thyroid cancer	7.79e-05	0.00253	CbGeAlD
Sunitinib—DAPK3—thyroid gland—thyroid cancer	7.77e-05	0.00252	CbGeAlD
Sunitinib—MYLK—head—thyroid cancer	7.73e-05	0.00251	CbGeAlD
Sunitinib—CYP3A4—Doxorubicin—thyroid cancer	7.72e-05	0.000322	CbGbCtD
Sunitinib—CLK2—thyroid gland—thyroid cancer	7.7e-05	0.0025	CbGeAlD
Sunitinib—IRAK4—trachea—thyroid cancer	7.67e-05	0.00249	CbGeAlD
Sunitinib—MAP4K2—thyroid gland—thyroid cancer	7.66e-05	0.00248	CbGeAlD
Sunitinib—KIT—neck—thyroid cancer	7.64e-05	0.00248	CbGeAlD
Sunitinib—YES1—saliva-secreting gland—thyroid cancer	7.6e-05	0.00246	CbGeAlD
Sunitinib—STK17A—lymph node—thyroid cancer	7.6e-05	0.00246	CbGeAlD
Sunitinib—STK4—head—thyroid cancer	7.59e-05	0.00246	CbGeAlD
Sunitinib—STK3—thyroid gland—thyroid cancer	7.56e-05	0.00245	CbGeAlD
Sunitinib—TAOK3—saliva-secreting gland—thyroid cancer	7.51e-05	0.00243	CbGeAlD
Sunitinib—ULK3—trachea—thyroid cancer	7.5e-05	0.00243	CbGeAlD
Sunitinib—CDK14—lymph node—thyroid cancer	7.49e-05	0.00243	CbGeAlD
Sunitinib—PDGFRB—neck—thyroid cancer	7.47e-05	0.00242	CbGeAlD
Sunitinib—PHKG2—head—thyroid cancer	7.46e-05	0.00242	CbGeAlD
Sunitinib—STK24—head—thyroid cancer	7.42e-05	0.0024	CbGeAlD
Sunitinib—CDK16—lymph node—thyroid cancer	7.39e-05	0.00239	CbGeAlD
Sunitinib—LATS2—lymph node—thyroid cancer	7.39e-05	0.00239	CbGeAlD
Sunitinib—PAK3—lymph node—thyroid cancer	7.39e-05	0.00239	CbGeAlD
Sunitinib—MAP3K7—trachea—thyroid cancer	7.37e-05	0.00239	CbGeAlD
Sunitinib—TBK1—trachea—thyroid cancer	7.29e-05	0.00236	CbGeAlD
Sunitinib—RPS6KA5—lymph node—thyroid cancer	7.29e-05	0.00236	CbGeAlD
Sunitinib—DYRK1A—thyroid gland—thyroid cancer	7.28e-05	0.00236	CbGeAlD
Sunitinib—TYK2—trachea—thyroid cancer	7.24e-05	0.00235	CbGeAlD
Sunitinib—STK16—head—thyroid cancer	7.21e-05	0.00234	CbGeAlD
Sunitinib—HIPK2—head—thyroid cancer	7.18e-05	0.00233	CbGeAlD
Sunitinib—ALK—head—thyroid cancer	7.18e-05	0.00233	CbGeAlD
Sunitinib—TYRO3—head—thyroid cancer	7.18e-05	0.00233	CbGeAlD
Sunitinib—MERTK—thyroid gland—thyroid cancer	7.11e-05	0.0023	CbGeAlD
Sunitinib—RIOK2—head—thyroid cancer	7.1e-05	0.0023	CbGeAlD
Sunitinib—MAP3K19—head—thyroid cancer	7.03e-05	0.00228	CbGeAlD
Sunitinib—CLK4—lymph node—thyroid cancer	7.01e-05	0.00227	CbGeAlD
Sunitinib—RPS6KB1—trachea—thyroid cancer	7.01e-05	0.00227	CbGeAlD
Sunitinib—MAP4K4—thyroid gland—thyroid cancer	6.98e-05	0.00226	CbGeAlD
Sunitinib—AXL—trachea—thyroid cancer	6.94e-05	0.00225	CbGeAlD
Sunitinib—ITK—lymph node—thyroid cancer	6.93e-05	0.00225	CbGeAlD
Sunitinib—SBK1—lymph node—thyroid cancer	6.93e-05	0.00225	CbGeAlD
Sunitinib—NUAK2—thyroid gland—thyroid cancer	6.93e-05	0.00225	CbGeAlD
Sunitinib—DAPK3—head—thyroid cancer	6.89e-05	0.00224	CbGeAlD
Sunitinib—MAP3K12—thyroid gland—thyroid cancer	6.88e-05	0.00223	CbGeAlD
Sunitinib—BLK—lymph node—thyroid cancer	6.85e-05	0.00222	CbGeAlD
Sunitinib—CLK2—head—thyroid cancer	6.83e-05	0.00221	CbGeAlD
Sunitinib—RPS6KA3—thyroid gland—thyroid cancer	6.78e-05	0.0022	CbGeAlD
Sunitinib—PHKG1—lymph node—thyroid cancer	6.77e-05	0.0022	CbGeAlD
Sunitinib—DAPK1—lymph node—thyroid cancer	6.77e-05	0.0022	CbGeAlD
Sunitinib—KDR—saliva-secreting gland—thyroid cancer	6.73e-05	0.00218	CbGeAlD
Sunitinib—MAP2K5—saliva-secreting gland—thyroid cancer	6.73e-05	0.00218	CbGeAlD
Sunitinib—STK3—head—thyroid cancer	6.71e-05	0.00217	CbGeAlD
Sunitinib—SLK—trachea—thyroid cancer	6.68e-05	0.00217	CbGeAlD
Sunitinib—CSNK1A1—thyroid gland—thyroid cancer	6.65e-05	0.00216	CbGeAlD
Sunitinib—ROCK1—head—thyroid cancer	6.62e-05	0.00215	CbGeAlD
Sunitinib—CLK1—thyroid gland—thyroid cancer	6.61e-05	0.00214	CbGeAlD
Sunitinib—JAK2—trachea—thyroid cancer	6.59e-05	0.00214	CbGeAlD
Sunitinib—STK11—lymph node—thyroid cancer	6.56e-05	0.00213	CbGeAlD
Sunitinib—BRD4—lymph node—thyroid cancer	6.56e-05	0.00213	CbGeAlD
Sunitinib—FYN—trachea—thyroid cancer	6.5e-05	0.00211	CbGeAlD
Sunitinib—RIOK1—lymph node—thyroid cancer	6.5e-05	0.00211	CbGeAlD
Sunitinib—RPS6KA1—lymph node—thyroid cancer	6.5e-05	0.00211	CbGeAlD
Sunitinib—CAMK2G—thyroid gland—thyroid cancer	6.49e-05	0.0021	CbGeAlD
Sunitinib—BMP2K—thyroid gland—thyroid cancer	6.49e-05	0.0021	CbGeAlD
Sunitinib—DYRK1A—head—thyroid cancer	6.46e-05	0.00209	CbGeAlD
Sunitinib—LRRK2—thyroid gland—thyroid cancer	6.43e-05	0.00208	CbGeAlD
Sunitinib—MARK2—lymph node—thyroid cancer	6.37e-05	0.00207	CbGeAlD
Sunitinib—TNIK—lymph node—thyroid cancer	6.37e-05	0.00207	CbGeAlD
Sunitinib—MAP4K5—trachea—thyroid cancer	6.35e-05	0.00206	CbGeAlD
Sunitinib—MAP3K3—trachea—thyroid cancer	6.35e-05	0.00206	CbGeAlD
Sunitinib—PRKAA1—thyroid gland—thyroid cancer	6.33e-05	0.00205	CbGeAlD
Sunitinib—SGK3—lymph node—thyroid cancer	6.31e-05	0.00205	CbGeAlD
Sunitinib—MERTK—head—thyroid cancer	6.31e-05	0.00204	CbGeAlD
Sunitinib—PTK2B—thyroid gland—thyroid cancer	6.26e-05	0.00203	CbGeAlD
Sunitinib—ICK—lymph node—thyroid cancer	6.25e-05	0.00203	CbGeAlD
Sunitinib—FLT4—thyroid gland—thyroid cancer	6.25e-05	0.00203	CbGeAlD
Sunitinib—MAP4K4—head—thyroid cancer	6.19e-05	0.00201	CbGeAlD
Sunitinib—CSNK1E—thyroid gland—thyroid cancer	6.16e-05	0.002	CbGeAlD
Sunitinib—FGFR1—thyroid gland—thyroid cancer	6.16e-05	0.002	CbGeAlD
Sunitinib—FLT1—trachea—thyroid cancer	6.14e-05	0.00199	CbGeAlD
Sunitinib—MAP3K12—head—thyroid cancer	6.1e-05	0.00198	CbGeAlD
Sunitinib—EPHB6—trachea—thyroid cancer	6.07e-05	0.00197	CbGeAlD
Sunitinib—IRAK4—thyroid gland—thyroid cancer	6.07e-05	0.00197	CbGeAlD
Sunitinib—CHEK2—lymph node—thyroid cancer	6.04e-05	0.00196	CbGeAlD
Sunitinib—NUAK1—lymph node—thyroid cancer	6.04e-05	0.00196	CbGeAlD
Sunitinib—RPS6KA3—head—thyroid cancer	6.02e-05	0.00195	CbGeAlD
Sunitinib—SNRK—lymph node—thyroid cancer	5.99e-05	0.00194	CbGeAlD
Sunitinib—INSR—lymph node—thyroid cancer	5.99e-05	0.00194	CbGeAlD
Sunitinib—OXSR1—lymph node—thyroid cancer	5.99e-05	0.00194	CbGeAlD
Sunitinib—MAP2K1—head—thyroid cancer	5.98e-05	0.00194	CbGeAlD
Sunitinib—KIT—saliva-secreting gland—thyroid cancer	5.96e-05	0.00193	CbGeAlD
Sunitinib—MAP2K2—thyroid gland—thyroid cancer	5.93e-05	0.00192	CbGeAlD
Sunitinib—ULK3—thyroid gland—thyroid cancer	5.93e-05	0.00192	CbGeAlD
Sunitinib—CSNK1A1—head—thyroid cancer	5.9e-05	0.00191	CbGeAlD
Sunitinib—STK38—lymph node—thyroid cancer	5.89e-05	0.00191	CbGeAlD
Sunitinib—RPS6KA2—lymph node—thyroid cancer	5.89e-05	0.00191	CbGeAlD
Sunitinib—MAP3K2—thyroid gland—thyroid cancer	5.89e-05	0.00191	CbGeAlD
Sunitinib—YES1—trachea—thyroid cancer	5.86e-05	0.0019	CbGeAlD
Sunitinib—CLK1—head—thyroid cancer	5.86e-05	0.0019	CbGeAlD
Sunitinib—AURKC—lymph node—thyroid cancer	5.85e-05	0.0019	CbGeAlD
Sunitinib—MAP3K7—thyroid gland—thyroid cancer	5.83e-05	0.00189	CbGeAlD
Sunitinib—PDGFRB—saliva-secreting gland—thyroid cancer	5.82e-05	0.00189	CbGeAlD
Sunitinib—CSNK1G2—lymph node—thyroid cancer	5.8e-05	0.00188	CbGeAlD
Sunitinib—PKN1—lymph node—thyroid cancer	5.8e-05	0.00188	CbGeAlD
Sunitinib—TAOK3—trachea—thyroid cancer	5.79e-05	0.00188	CbGeAlD
Sunitinib—TBK1—thyroid gland—thyroid cancer	5.77e-05	0.00187	CbGeAlD
Sunitinib—BMP2K—head—thyroid cancer	5.75e-05	0.00187	CbGeAlD
Sunitinib—CAMK2G—head—thyroid cancer	5.75e-05	0.00187	CbGeAlD
Sunitinib—PDGFRA—trachea—thyroid cancer	5.75e-05	0.00187	CbGeAlD
Sunitinib—TYK2—thyroid gland—thyroid cancer	5.73e-05	0.00186	CbGeAlD
Sunitinib—PRPF4—lymph node—thyroid cancer	5.72e-05	0.00185	CbGeAlD
Sunitinib—LRRK2—head—thyroid cancer	5.7e-05	0.00185	CbGeAlD
Sunitinib—IRAK1—thyroid gland—thyroid cancer	5.65e-05	0.00183	CbGeAlD
Sunitinib—PRPF4B—lymph node—thyroid cancer	5.64e-05	0.00183	CbGeAlD
Sunitinib—PRKAA1—head—thyroid cancer	5.62e-05	0.00182	CbGeAlD
Sunitinib—STK39—lymph node—thyroid cancer	5.56e-05	0.0018	CbGeAlD
Sunitinib—PTK2B—head—thyroid cancer	5.56e-05	0.0018	CbGeAlD
Sunitinib—RPS6KB1—thyroid gland—thyroid cancer	5.55e-05	0.0018	CbGeAlD
Sunitinib—FLT4—head—thyroid cancer	5.54e-05	0.0018	CbGeAlD
Sunitinib—FGR—thyroid gland—thyroid cancer	5.51e-05	0.00179	CbGeAlD
Sunitinib—RET—thyroid gland—thyroid cancer	5.51e-05	0.00179	CbGeAlD
Sunitinib—AXL—thyroid gland—thyroid cancer	5.49e-05	0.00178	CbGeAlD
Sunitinib—CSNK2A1—lymph node—thyroid cancer	5.49e-05	0.00178	CbGeAlD
Sunitinib—CSNK1E—head—thyroid cancer	5.47e-05	0.00177	CbGeAlD
Sunitinib—MYLK—lymph node—thyroid cancer	5.42e-05	0.00176	CbGeAlD
Sunitinib—IRAK4—head—thyroid cancer	5.38e-05	0.00174	CbGeAlD
Sunitinib—PLK4—lymph node—thyroid cancer	5.35e-05	0.00173	CbGeAlD
Sunitinib—STK4—lymph node—thyroid cancer	5.32e-05	0.00172	CbGeAlD
Sunitinib—SLK—thyroid gland—thyroid cancer	5.29e-05	0.00171	CbGeAlD
Sunitinib—MAP2K2—head—thyroid cancer	5.26e-05	0.00171	CbGeAlD
Sunitinib—ULK3—head—thyroid cancer	5.26e-05	0.00171	CbGeAlD
Sunitinib—FGFR2—thyroid gland—thyroid cancer	5.24e-05	0.0017	CbGeAlD
Sunitinib—MAP3K2—head—thyroid cancer	5.22e-05	0.00169	CbGeAlD
Sunitinib—PHKG2—lymph node—thyroid cancer	5.22e-05	0.00169	CbGeAlD
Sunitinib—JAK2—thyroid gland—thyroid cancer	5.21e-05	0.00169	CbGeAlD
Sunitinib—STK24—lymph node—thyroid cancer	5.19e-05	0.00168	CbGeAlD
Sunitinib—KDR—trachea—thyroid cancer	5.19e-05	0.00168	CbGeAlD
Sunitinib—MAP2K5—trachea—thyroid cancer	5.19e-05	0.00168	CbGeAlD
Sunitinib—FYN—thyroid gland—thyroid cancer	5.14e-05	0.00167	CbGeAlD
Sunitinib—DAPK2—lymph node—thyroid cancer	5.13e-05	0.00166	CbGeAlD
Sunitinib—TBK1—head—thyroid cancer	5.12e-05	0.00166	CbGeAlD
Sunitinib—TYK2—head—thyroid cancer	5.08e-05	0.00165	CbGeAlD
Sunitinib—CSF1R—trachea—thyroid cancer	5.07e-05	0.00164	CbGeAlD
Sunitinib—STK16—lymph node—thyroid cancer	5.05e-05	0.00164	CbGeAlD
Sunitinib—HIPK3—lymph node—thyroid cancer	5.02e-05	0.00163	CbGeAlD
Sunitinib—HIPK2—lymph node—thyroid cancer	5.02e-05	0.00163	CbGeAlD
Sunitinib—ALK—lymph node—thyroid cancer	5.02e-05	0.00163	CbGeAlD
Sunitinib—MAP3K3—thyroid gland—thyroid cancer	5.02e-05	0.00163	CbGeAlD
Sunitinib—MAP4K5—thyroid gland—thyroid cancer	5.02e-05	0.00163	CbGeAlD
Sunitinib—TNK1—lymph node—thyroid cancer	4.97e-05	0.00161	CbGeAlD
Sunitinib—RIOK2—lymph node—thyroid cancer	4.97e-05	0.00161	CbGeAlD
Sunitinib—MAP4K1—lymph node—thyroid cancer	4.92e-05	0.0016	CbGeAlD
Sunitinib—RPS6KB1—head—thyroid cancer	4.92e-05	0.0016	CbGeAlD
Sunitinib—FGR—head—thyroid cancer	4.89e-05	0.00159	CbGeAlD
Sunitinib—RET—head—thyroid cancer	4.89e-05	0.00159	CbGeAlD
Sunitinib—AXL—head—thyroid cancer	4.87e-05	0.00158	CbGeAlD
Sunitinib—FLT1—thyroid gland—thyroid cancer	4.86e-05	0.00157	CbGeAlD
Sunitinib—DAPK3—lymph node—thyroid cancer	4.83e-05	0.00157	CbGeAlD
Sunitinib—EPHB6—thyroid gland—thyroid cancer	4.8e-05	0.00156	CbGeAlD
Sunitinib—CLK2—lymph node—thyroid cancer	4.78e-05	0.00155	CbGeAlD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—thyroid cancer	4.77e-05	0.053	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—thyroid cancer	4.77e-05	0.053	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—thyroid cancer	4.77e-05	0.053	CbGdCrCtD
Sunitinib—MAP4K2—lymph node—thyroid cancer	4.76e-05	0.00154	CbGeAlD
Sunitinib—STK3—lymph node—thyroid cancer	4.7e-05	0.00152	CbGeAlD
Sunitinib—FGFR2—head—thyroid cancer	4.65e-05	0.00151	CbGeAlD
Sunitinib—YES1—thyroid gland—thyroid cancer	4.64e-05	0.0015	CbGeAlD
Sunitinib—JAK2—head—thyroid cancer	4.62e-05	0.0015	CbGeAlD
Sunitinib—KIT—trachea—thyroid cancer	4.6e-05	0.00149	CbGeAlD
Sunitinib—STK10—thyroid gland—thyroid cancer	4.6e-05	0.00149	CbGeAlD
Sunitinib—TAOK3—thyroid gland—thyroid cancer	4.58e-05	0.00148	CbGeAlD
Sunitinib—FYN—head—thyroid cancer	4.56e-05	0.00148	CbGeAlD
Sunitinib—PDGFRA—thyroid gland—thyroid cancer	4.55e-05	0.00148	CbGeAlD
Sunitinib—DYRK1A—lymph node—thyroid cancer	4.52e-05	0.00147	CbGeAlD
Sunitinib—PDGFRB—trachea—thyroid cancer	4.49e-05	0.00146	CbGeAlD
Sunitinib—MAP3K3—head—thyroid cancer	4.46e-05	0.00144	CbGeAlD
Sunitinib—MAP4K5—head—thyroid cancer	4.46e-05	0.00144	CbGeAlD
Sunitinib—MERTK—lymph node—thyroid cancer	4.42e-05	0.00143	CbGeAlD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—thyroid cancer	4.41e-05	0.049	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—thyroid cancer	4.41e-05	0.049	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—thyroid cancer	4.41e-05	0.049	CbGdCrCtD
Sunitinib—MAP4K4—lymph node—thyroid cancer	4.33e-05	0.00141	CbGeAlD
Sunitinib—FLT1—head—thyroid cancer	4.31e-05	0.0014	CbGeAlD
Sunitinib—NUAK2—lymph node—thyroid cancer	4.3e-05	0.00139	CbGeAlD
Sunitinib—FLT3—lymph node—thyroid cancer	4.27e-05	0.00139	CbGeAlD
Sunitinib—MAP3K12—lymph node—thyroid cancer	4.27e-05	0.00139	CbGeAlD
Sunitinib—EPHB6—head—thyroid cancer	4.26e-05	0.00138	CbGeAlD
Sunitinib—RPS6KA3—lymph node—thyroid cancer	4.21e-05	0.00137	CbGeAlD
Sunitinib—MAP2K1—lymph node—thyroid cancer	4.19e-05	0.00136	CbGeAlD
Sunitinib—CSNK1A1—lymph node—thyroid cancer	4.13e-05	0.00134	CbGeAlD
Sunitinib—YES1—head—thyroid cancer	4.12e-05	0.00133	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—thyroid cancer	4.12e-05	0.0457	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—thyroid cancer	4.12e-05	0.0457	CbGdCrCtD
Sunitinib—KDR—thyroid gland—thyroid cancer	4.11e-05	0.00133	CbGeAlD
Sunitinib—MAP2K5—thyroid gland—thyroid cancer	4.11e-05	0.00133	CbGeAlD
Sunitinib—CLK1—lymph node—thyroid cancer	4.1e-05	0.00133	CbGeAlD
Sunitinib—STK10—head—thyroid cancer	4.08e-05	0.00132	CbGeAlD
Sunitinib—TAOK3—head—thyroid cancer	4.06e-05	0.00132	CbGeAlD
Sunitinib—PDGFRA—head—thyroid cancer	4.04e-05	0.00131	CbGeAlD
Sunitinib—CAMK2G—lymph node—thyroid cancer	4.03e-05	0.00131	CbGeAlD
Sunitinib—BMP2K—lymph node—thyroid cancer	4.03e-05	0.00131	CbGeAlD
Sunitinib—CSF1R—thyroid gland—thyroid cancer	4.01e-05	0.0013	CbGeAlD
Sunitinib—LRRK2—lymph node—thyroid cancer	3.99e-05	0.00129	CbGeAlD
Sunitinib—PRKAA1—lymph node—thyroid cancer	3.94e-05	0.00128	CbGeAlD
Sunitinib—PTK2B—lymph node—thyroid cancer	3.89e-05	0.00126	CbGeAlD
Sunitinib—FLT4—lymph node—thyroid cancer	3.88e-05	0.00126	CbGeAlD
Sunitinib—CSNK1E—lymph node—thyroid cancer	3.83e-05	0.00124	CbGeAlD
Sunitinib—FGFR1—lymph node—thyroid cancer	3.83e-05	0.00124	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—thyroid cancer	3.81e-05	0.0423	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—thyroid cancer	3.81e-05	0.0423	CbGdCrCtD
Sunitinib—IRAK4—lymph node—thyroid cancer	3.77e-05	0.00122	CbGeAlD
Sunitinib—ULK3—lymph node—thyroid cancer	3.68e-05	0.00119	CbGeAlD
Sunitinib—MAP2K2—lymph node—thyroid cancer	3.68e-05	0.00119	CbGeAlD
Sunitinib—MAP3K2—lymph node—thyroid cancer	3.66e-05	0.00119	CbGeAlD
Sunitinib—KDR—head—thyroid cancer	3.64e-05	0.00118	CbGeAlD
Sunitinib—MAP2K5—head—thyroid cancer	3.64e-05	0.00118	CbGeAlD
Sunitinib—KIT—thyroid gland—thyroid cancer	3.64e-05	0.00118	CbGeAlD
Sunitinib—MAP3K7—lymph node—thyroid cancer	3.62e-05	0.00118	CbGeAlD
Sunitinib—TBK1—lymph node—thyroid cancer	3.58e-05	0.00116	CbGeAlD
Sunitinib—TYK2—lymph node—thyroid cancer	3.56e-05	0.00115	CbGeAlD
Sunitinib—CSF1R—head—thyroid cancer	3.55e-05	0.00115	CbGeAlD
Sunitinib—PDGFRB—thyroid gland—thyroid cancer	3.55e-05	0.00115	CbGeAlD
Sunitinib—IRAK1—lymph node—thyroid cancer	3.51e-05	0.00114	CbGeAlD
Sunitinib—RPS6KB1—lymph node—thyroid cancer	3.45e-05	0.00112	CbGeAlD
Sunitinib—RET—lymph node—thyroid cancer	3.43e-05	0.00111	CbGeAlD
Sunitinib—FGR—lymph node—thyroid cancer	3.43e-05	0.00111	CbGeAlD
Sunitinib—AXL—lymph node—thyroid cancer	3.41e-05	0.00111	CbGeAlD
Sunitinib—SLK—lymph node—thyroid cancer	3.28e-05	0.00106	CbGeAlD
Sunitinib—ABCG2—saliva-secreting gland—thyroid cancer	3.27e-05	0.00106	CbGeAlD
Sunitinib—PLK4—Idarubicin—Epirubicin—thyroid cancer	3.26e-05	0.0362	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—thyroid cancer	3.26e-05	0.0362	CbGdCrCtD
Sunitinib—JAK2—lymph node—thyroid cancer	3.24e-05	0.00105	CbGeAlD
Sunitinib—KIT—head—thyroid cancer	3.23e-05	0.00105	CbGeAlD
Sunitinib—FYN—lymph node—thyroid cancer	3.19e-05	0.00104	CbGeAlD
Sunitinib—PDGFRB—head—thyroid cancer	3.15e-05	0.00102	CbGeAlD
Sunitinib—MAP4K5—lymph node—thyroid cancer	3.12e-05	0.00101	CbGeAlD
Sunitinib—MAP3K3—lymph node—thyroid cancer	3.12e-05	0.00101	CbGeAlD
Sunitinib—FLT1—lymph node—thyroid cancer	3.02e-05	0.000978	CbGeAlD
Sunitinib—PLK4—Epirubicin—Doxorubicin—thyroid cancer	3.01e-05	0.0335	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—thyroid cancer	3.01e-05	0.0335	CbGdCrCtD
Sunitinib—EPHB6—lymph node—thyroid cancer	2.98e-05	0.000967	CbGeAlD
Sunitinib—YES1—lymph node—thyroid cancer	2.88e-05	0.000934	CbGeAlD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—thyroid cancer	2.87e-05	0.0319	CbGdCrCtD
Sunitinib—STK10—lymph node—thyroid cancer	2.86e-05	0.000926	CbGeAlD
Sunitinib—TAOK3—lymph node—thyroid cancer	2.85e-05	0.000922	CbGeAlD
Sunitinib—ABCC4—thyroid gland—thyroid cancer	2.83e-05	0.000917	CbGeAlD
Sunitinib—PDGFRA—lymph node—thyroid cancer	2.83e-05	0.000917	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—thyroid cancer	2.66e-05	0.0295	CbGdCrCtD
Sunitinib—Nausea—Vandetanib—thyroid cancer	2.61e-05	0.000564	CcSEcCtD
Sunitinib—Dyspepsia—Sorafenib—thyroid cancer	2.61e-05	0.000564	CcSEcCtD
Sunitinib—Oesophagitis—Doxorubicin—thyroid cancer	2.6e-05	0.000561	CcSEcCtD
Sunitinib—Rash maculo-papular—Doxorubicin—thyroid cancer	2.58e-05	0.000558	CcSEcCtD
Sunitinib—Decreased appetite—Sorafenib—thyroid cancer	2.58e-05	0.000557	CcSEcCtD
Sunitinib—Neoplasm—Doxorubicin—thyroid cancer	2.57e-05	0.000555	CcSEcCtD
Sunitinib—Mouth ulceration—Doxorubicin—thyroid cancer	2.57e-05	0.000555	CcSEcCtD
Sunitinib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	2.56e-05	0.000554	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	2.56e-05	0.000553	CcSEcCtD
Sunitinib—Fatigue—Sorafenib—thyroid cancer	2.56e-05	0.000552	CcSEcCtD
Sunitinib—Hepatic function abnormal—Epirubicin—thyroid cancer	2.55e-05	0.000551	CcSEcCtD
Sunitinib—KDR—lymph node—thyroid cancer	2.55e-05	0.000827	CbGeAlD
Sunitinib—MAP2K5—lymph node—thyroid cancer	2.55e-05	0.000827	CbGeAlD
Sunitinib—Constipation—Sorafenib—thyroid cancer	2.54e-05	0.000548	CcSEcCtD
Sunitinib—Pain—Sorafenib—thyroid cancer	2.54e-05	0.000548	CcSEcCtD
Sunitinib—Pulmonary oedema—Doxorubicin—thyroid cancer	2.53e-05	0.000546	CcSEcCtD
Sunitinib—ABCC4—head—thyroid cancer	2.51e-05	0.000814	CbGeAlD
Sunitinib—CSF1R—lymph node—thyroid cancer	2.49e-05	0.000807	CbGeAlD
Sunitinib—Hepatic failure—Epirubicin—thyroid cancer	2.48e-05	0.000536	CcSEcCtD
Sunitinib—Eczema—Epirubicin—thyroid cancer	2.48e-05	0.000536	CcSEcCtD
Sunitinib—Sepsis—Doxorubicin—thyroid cancer	2.47e-05	0.000533	CcSEcCtD
Sunitinib—Cardiac failure congestive—Epirubicin—thyroid cancer	2.46e-05	0.000531	CcSEcCtD
Sunitinib—Gastrointestinal pain—Sorafenib—thyroid cancer	2.43e-05	0.000524	CcSEcCtD
Sunitinib—Renal failure acute—Epirubicin—thyroid cancer	2.42e-05	0.000522	CcSEcCtD
Sunitinib—Hot flush—Epirubicin—thyroid cancer	2.38e-05	0.000515	CcSEcCtD
Sunitinib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	2.37e-05	0.000512	CcSEcCtD
Sunitinib—Menopausal symptoms—Epirubicin—thyroid cancer	2.36e-05	0.00051	CcSEcCtD
Sunitinib—Hepatic function abnormal—Doxorubicin—thyroid cancer	2.36e-05	0.00051	CcSEcCtD
Sunitinib—Abdominal pain—Sorafenib—thyroid cancer	2.34e-05	0.000506	CcSEcCtD
Sunitinib—Body temperature increased—Sorafenib—thyroid cancer	2.34e-05	0.000506	CcSEcCtD
Sunitinib—Renal impairment—Epirubicin—thyroid cancer	2.34e-05	0.000506	CcSEcCtD
Sunitinib—Dermatitis bullous—Epirubicin—thyroid cancer	2.33e-05	0.000504	CcSEcCtD
Sunitinib—Eczema—Doxorubicin—thyroid cancer	2.3e-05	0.000496	CcSEcCtD
Sunitinib—Hepatic failure—Doxorubicin—thyroid cancer	2.3e-05	0.000496	CcSEcCtD
Sunitinib—Hypoglycaemia—Epirubicin—thyroid cancer	2.29e-05	0.000493	CcSEcCtD
Sunitinib—Cardiac failure—Epirubicin—thyroid cancer	2.29e-05	0.000493	CcSEcCtD
Sunitinib—Cerebrovascular accident—Epirubicin—thyroid cancer	2.28e-05	0.000491	CcSEcCtD
Sunitinib—Cardiac failure congestive—Doxorubicin—thyroid cancer	2.28e-05	0.000491	CcSEcCtD
Sunitinib—KIT—lymph node—thyroid cancer	2.26e-05	0.000733	CbGeAlD
Sunitinib—Hyponatraemia—Epirubicin—thyroid cancer	2.24e-05	0.000483	CcSEcCtD
Sunitinib—Renal failure acute—Doxorubicin—thyroid cancer	2.24e-05	0.000483	CcSEcCtD
Sunitinib—Pain in extremity—Epirubicin—thyroid cancer	2.23e-05	0.000482	CcSEcCtD
Sunitinib—PDGFRB—lymph node—thyroid cancer	2.21e-05	0.000716	CbGeAlD
Sunitinib—Hot flush—Doxorubicin—thyroid cancer	2.21e-05	0.000476	CcSEcCtD
Sunitinib—Menopausal symptoms—Doxorubicin—thyroid cancer	2.19e-05	0.000472	CcSEcCtD
Sunitinib—Hypersensitivity—Sorafenib—thyroid cancer	2.19e-05	0.000472	CcSEcCtD
Sunitinib—Renal impairment—Doxorubicin—thyroid cancer	2.17e-05	0.000468	CcSEcCtD
Sunitinib—Dermatitis bullous—Doxorubicin—thyroid cancer	2.16e-05	0.000466	CcSEcCtD
Sunitinib—Face oedema—Epirubicin—thyroid cancer	2.15e-05	0.000465	CcSEcCtD
Sunitinib—Asthenia—Sorafenib—thyroid cancer	2.13e-05	0.000459	CcSEcCtD
Sunitinib—Cardiac failure—Doxorubicin—thyroid cancer	2.11e-05	0.000457	CcSEcCtD
Sunitinib—Hypoglycaemia—Doxorubicin—thyroid cancer	2.11e-05	0.000457	CcSEcCtD
Sunitinib—Cerebrovascular accident—Doxorubicin—thyroid cancer	2.11e-05	0.000455	CcSEcCtD
Sunitinib—Pruritus—Sorafenib—thyroid cancer	2.1e-05	0.000453	CcSEcCtD
Sunitinib—Blood creatinine increased—Epirubicin—thyroid cancer	2.09e-05	0.000451	CcSEcCtD
Sunitinib—Dehydration—Epirubicin—thyroid cancer	2.07e-05	0.000448	CcSEcCtD
Sunitinib—Hyponatraemia—Doxorubicin—thyroid cancer	2.07e-05	0.000447	CcSEcCtD
Sunitinib—Pain in extremity—Doxorubicin—thyroid cancer	2.06e-05	0.000446	CcSEcCtD
Sunitinib—Liver function test abnormal—Epirubicin—thyroid cancer	2.06e-05	0.000445	CcSEcCtD
Sunitinib—Dry skin—Epirubicin—thyroid cancer	2.04e-05	0.000441	CcSEcCtD
Sunitinib—Abdominal pain upper—Epirubicin—thyroid cancer	2.04e-05	0.00044	CcSEcCtD
Sunitinib—Hypokalaemia—Epirubicin—thyroid cancer	2.03e-05	0.000438	CcSEcCtD
Sunitinib—Diarrhoea—Sorafenib—thyroid cancer	2.03e-05	0.000438	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	2.01e-05	0.000434	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	2.01e-05	0.000434	CcSEcCtD
Sunitinib—ABCG2—thyroid gland—thyroid cancer	2e-05	0.000648	CbGeAlD
Sunitinib—Nasopharyngitis—Epirubicin—thyroid cancer	1.99e-05	0.000431	CcSEcCtD
Sunitinib—Face oedema—Doxorubicin—thyroid cancer	1.99e-05	0.00043	CcSEcCtD
Sunitinib—KCNH2—head—thyroid cancer	1.99e-05	0.000646	CbGeAlD
Sunitinib—Muscular weakness—Epirubicin—thyroid cancer	1.97e-05	0.000425	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	1.97e-05	0.000425	CcSEcCtD
Sunitinib—Dizziness—Sorafenib—thyroid cancer	1.96e-05	0.000423	CcSEcCtD
Sunitinib—Abdominal distension—Epirubicin—thyroid cancer	1.94e-05	0.000419	CcSEcCtD
Sunitinib—Blood creatinine increased—Doxorubicin—thyroid cancer	1.93e-05	0.000417	CcSEcCtD
Sunitinib—Dysphagia—Epirubicin—thyroid cancer	1.93e-05	0.000416	CcSEcCtD
Sunitinib—Dehydration—Doxorubicin—thyroid cancer	1.92e-05	0.000414	CcSEcCtD
Sunitinib—Liver function test abnormal—Doxorubicin—thyroid cancer	1.91e-05	0.000411	CcSEcCtD
Sunitinib—Dry skin—Doxorubicin—thyroid cancer	1.89e-05	0.000408	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—thyroid cancer	1.89e-05	0.000408	CcSEcCtD
Sunitinib—Vomiting—Sorafenib—thyroid cancer	1.89e-05	0.000407	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—thyroid cancer	1.88e-05	0.000407	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—thyroid cancer	1.88e-05	0.000406	CcSEcCtD
Sunitinib—Rash—Sorafenib—thyroid cancer	1.87e-05	0.000404	CcSEcCtD
Sunitinib—Dermatitis—Sorafenib—thyroid cancer	1.87e-05	0.000403	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	1.86e-05	0.000401	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	1.86e-05	0.000401	CcSEcCtD
Sunitinib—Headache—Sorafenib—thyroid cancer	1.86e-05	0.000401	CcSEcCtD
Sunitinib—Bronchitis—Epirubicin—thyroid cancer	1.85e-05	0.0004	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—thyroid cancer	1.85e-05	0.000398	CcSEcCtD
Sunitinib—Pancytopenia—Epirubicin—thyroid cancer	1.83e-05	0.000395	CcSEcCtD
Sunitinib—Muscular weakness—Doxorubicin—thyroid cancer	1.82e-05	0.000393	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	1.82e-05	0.000393	CcSEcCtD
Sunitinib—Neutropenia—Epirubicin—thyroid cancer	1.8e-05	0.000389	CcSEcCtD
Sunitinib—Abdominal distension—Doxorubicin—thyroid cancer	1.8e-05	0.000388	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	1.79e-05	0.000387	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—thyroid cancer	1.78e-05	0.000385	CcSEcCtD
Sunitinib—Nausea—Sorafenib—thyroid cancer	1.76e-05	0.00038	CcSEcCtD
Sunitinib—ABCC4—lymph node—thyroid cancer	1.76e-05	0.00057	CbGeAlD
Sunitinib—Pancreatitis—Doxorubicin—thyroid cancer	1.75e-05	0.000378	CcSEcCtD
Sunitinib—Weight decreased—Epirubicin—thyroid cancer	1.74e-05	0.000377	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—thyroid cancer	1.74e-05	0.000375	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—thyroid cancer	1.73e-05	0.000373	CcSEcCtD
Sunitinib—Infestation—Epirubicin—thyroid cancer	1.72e-05	0.000371	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—thyroid cancer	1.72e-05	0.000371	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—thyroid cancer	1.72e-05	0.00037	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	1.7e-05	0.000368	CcSEcCtD
Sunitinib—ABCC2—lymph node—thyroid cancer	1.7e-05	0.000552	CbGeAlD
Sunitinib—Pancytopenia—Doxorubicin—thyroid cancer	1.69e-05	0.000366	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—thyroid cancer	1.69e-05	0.000365	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—thyroid cancer	1.68e-05	0.000364	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—thyroid cancer	1.68e-05	0.000362	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—thyroid cancer	1.67e-05	0.000361	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—thyroid cancer	1.67e-05	0.00036	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	1.66e-05	0.000358	CcSEcCtD
Sunitinib—Hepatobiliary disease—Epirubicin—thyroid cancer	1.63e-05	0.000351	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—thyroid cancer	1.62e-05	0.00035	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—thyroid cancer	1.61e-05	0.000348	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—thyroid cancer	1.61e-05	0.000347	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—thyroid cancer	1.6e-05	0.000345	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—thyroid cancer	1.59e-05	0.000343	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—thyroid cancer	1.59e-05	0.000343	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	1.58e-05	0.00034	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—thyroid cancer	1.57e-05	0.000339	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—thyroid cancer	1.56e-05	0.000338	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	1.56e-05	0.000337	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—thyroid cancer	1.55e-05	0.000335	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—thyroid cancer	1.55e-05	0.000335	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—thyroid cancer	1.55e-05	0.000334	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—thyroid cancer	1.54e-05	0.000333	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—thyroid cancer	1.54e-05	0.000333	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—thyroid cancer	1.54e-05	0.000331	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—thyroid cancer	1.52e-05	0.000329	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—thyroid cancer	1.52e-05	0.000328	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—thyroid cancer	1.52e-05	0.000327	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—thyroid cancer	1.51e-05	0.000327	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	1.5e-05	0.000325	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—thyroid cancer	1.5e-05	0.000324	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—thyroid cancer	1.46e-05	0.000315	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—thyroid cancer	1.45e-05	0.000314	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—thyroid cancer	1.44e-05	0.000311	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—thyroid cancer	1.44e-05	0.00031	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—thyroid cancer	1.43e-05	0.000309	CcSEcCtD
Sunitinib—Flushing—Epirubicin—thyroid cancer	1.43e-05	0.000309	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—thyroid cancer	1.43e-05	0.000308	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—thyroid cancer	1.43e-05	0.000308	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—thyroid cancer	1.42e-05	0.000307	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—thyroid cancer	1.41e-05	0.000304	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—thyroid cancer	1.41e-05	0.000304	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—thyroid cancer	1.4e-05	0.000303	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—thyroid cancer	1.4e-05	0.000302	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—thyroid cancer	1.4e-05	0.000302	CcSEcCtD
Sunitinib—KCNH2—lymph node—thyroid cancer	1.39e-05	0.000452	CbGeAlD
Sunitinib—Immune system disorder—Epirubicin—thyroid cancer	1.39e-05	0.000301	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—thyroid cancer	1.39e-05	0.0003	CcSEcCtD
Sunitinib—Chills—Epirubicin—thyroid cancer	1.38e-05	0.000299	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—thyroid cancer	1.38e-05	0.000298	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—thyroid cancer	1.36e-05	0.000294	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—thyroid cancer	1.35e-05	0.000292	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—thyroid cancer	1.35e-05	0.000291	CcSEcCtD
Sunitinib—Erythema—Epirubicin—thyroid cancer	1.34e-05	0.00029	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—thyroid cancer	1.34e-05	0.00029	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—thyroid cancer	1.33e-05	0.000288	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—thyroid cancer	1.33e-05	0.000286	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—thyroid cancer	1.33e-05	0.000286	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—thyroid cancer	1.32e-05	0.000286	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—thyroid cancer	1.32e-05	0.000284	CcSEcCtD
Sunitinib—Back pain—Epirubicin—thyroid cancer	1.3e-05	0.000281	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—thyroid cancer	1.3e-05	0.00028	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—thyroid cancer	1.29e-05	0.000279	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—thyroid cancer	1.29e-05	0.000278	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—thyroid cancer	1.29e-05	0.000278	CcSEcCtD
Sunitinib—Chills—Doxorubicin—thyroid cancer	1.28e-05	0.000277	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—thyroid cancer	1.28e-05	0.000275	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—thyroid cancer	1.26e-05	0.000272	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—thyroid cancer	1.25e-05	0.00027	CcSEcCtD
Sunitinib—ABCB1—trachea—thyroid cancer	1.25e-05	0.000404	CbGeAlD
Sunitinib—Malnutrition—Doxorubicin—thyroid cancer	1.24e-05	0.000268	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—thyroid cancer	1.24e-05	0.000268	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—thyroid cancer	1.24e-05	0.000268	CcSEcCtD
Sunitinib—ABCG2—lymph node—thyroid cancer	1.24e-05	0.000402	CbGeAlD
Sunitinib—Flatulence—Doxorubicin—thyroid cancer	1.22e-05	0.000264	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—thyroid cancer	1.22e-05	0.000263	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—thyroid cancer	1.2e-05	0.00026	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—thyroid cancer	1.2e-05	0.00026	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—thyroid cancer	1.19e-05	0.000258	CcSEcCtD
Sunitinib—Cough—Epirubicin—thyroid cancer	1.17e-05	0.000253	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—thyroid cancer	1.16e-05	0.000251	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—thyroid cancer	1.16e-05	0.00025	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—thyroid cancer	1.15e-05	0.000248	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—thyroid cancer	1.14e-05	0.000247	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—thyroid cancer	1.14e-05	0.000247	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—thyroid cancer	1.14e-05	0.000247	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	1.14e-05	0.000245	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—thyroid cancer	1.12e-05	0.000241	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—thyroid cancer	1.11e-05	0.00024	CcSEcCtD
Sunitinib—Oedema—Epirubicin—thyroid cancer	1.1e-05	0.000237	CcSEcCtD
Sunitinib—Infection—Epirubicin—thyroid cancer	1.09e-05	0.000235	CcSEcCtD
Sunitinib—Cough—Doxorubicin—thyroid cancer	1.08e-05	0.000234	CcSEcCtD
Sunitinib—Shock—Epirubicin—thyroid cancer	1.08e-05	0.000233	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—thyroid cancer	1.08e-05	0.000232	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—thyroid cancer	1.08e-05	0.000232	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—thyroid cancer	1.07e-05	0.000232	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—thyroid cancer	1.07e-05	0.000232	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—thyroid cancer	1.06e-05	0.00023	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—thyroid cancer	1.06e-05	0.000228	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—thyroid cancer	1.06e-05	0.000228	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—thyroid cancer	1.06e-05	0.000228	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	1.05e-05	0.000227	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—thyroid cancer	1.04e-05	0.000226	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—thyroid cancer	1.03e-05	0.000223	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—thyroid cancer	1.01e-05	0.000219	CcSEcCtD
Sunitinib—Infection—Doxorubicin—thyroid cancer	1.01e-05	0.000218	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	9.99e-06	0.000216	CcSEcCtD
Sunitinib—Shock—Doxorubicin—thyroid cancer	9.98e-06	0.000215	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—thyroid cancer	9.95e-06	0.000215	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—thyroid cancer	9.93e-06	0.000214	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—thyroid cancer	9.92e-06	0.000214	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—thyroid cancer	9.85e-06	0.000213	CcSEcCtD
Sunitinib—ABCB1—thyroid gland—thyroid cancer	9.85e-06	0.000319	CbGeAlD
Sunitinib—Paraesthesia—Epirubicin—thyroid cancer	9.84e-06	0.000213	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—thyroid cancer	9.77e-06	0.000211	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—thyroid cancer	9.67e-06	0.000209	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—thyroid cancer	9.65e-06	0.000208	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—thyroid cancer	9.53e-06	0.000206	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	9.46e-06	0.000204	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—thyroid cancer	9.45e-06	0.000204	CcSEcCtD
Sunitinib—Constipation—Epirubicin—thyroid cancer	9.37e-06	0.000202	CcSEcCtD
Sunitinib—Pain—Epirubicin—thyroid cancer	9.37e-06	0.000202	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	9.24e-06	0.0002	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—thyroid cancer	9.17e-06	0.000198	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—thyroid cancer	9.11e-06	0.000197	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—thyroid cancer	9.04e-06	0.000195	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—thyroid cancer	8.96e-06	0.000194	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—thyroid cancer	8.93e-06	0.000193	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—thyroid cancer	8.82e-06	0.00019	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	8.76e-06	0.000189	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—thyroid cancer	8.75e-06	0.000189	CcSEcCtD
Sunitinib—ABCB1—head—thyroid cancer	8.74e-06	0.000283	CbGeAlD
Sunitinib—Constipation—Doxorubicin—thyroid cancer	8.67e-06	0.000187	CcSEcCtD
Sunitinib—Pain—Doxorubicin—thyroid cancer	8.67e-06	0.000187	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—thyroid cancer	8.67e-06	0.000187	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—thyroid cancer	8.67e-06	0.000187	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	8.29e-06	0.000179	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—thyroid cancer	8.08e-06	0.000174	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—thyroid cancer	8.02e-06	0.000173	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—thyroid cancer	8.02e-06	0.000173	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—thyroid cancer	7.87e-06	0.00017	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—thyroid cancer	7.76e-06	0.000167	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—thyroid cancer	7.5e-06	0.000162	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—thyroid cancer	7.47e-06	0.000161	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—thyroid cancer	7.28e-06	0.000157	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—thyroid cancer	7.25e-06	0.000157	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—thyroid cancer	7.18e-06	0.000155	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—thyroid cancer	6.97e-06	0.00015	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—thyroid cancer	6.94e-06	0.00015	CcSEcCtD
Sunitinib—Rash—Epirubicin—thyroid cancer	6.91e-06	0.000149	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—thyroid cancer	6.91e-06	0.000149	CcSEcCtD
Sunitinib—Headache—Epirubicin—thyroid cancer	6.87e-06	0.000148	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—thyroid cancer	6.71e-06	0.000145	CcSEcCtD
Sunitinib—Nausea—Epirubicin—thyroid cancer	6.51e-06	0.000141	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—thyroid cancer	6.45e-06	0.000139	CcSEcCtD
Sunitinib—Rash—Doxorubicin—thyroid cancer	6.4e-06	0.000138	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—thyroid cancer	6.39e-06	0.000138	CcSEcCtD
Sunitinib—Headache—Doxorubicin—thyroid cancer	6.35e-06	0.000137	CcSEcCtD
Sunitinib—ABCB1—lymph node—thyroid cancer	6.12e-06	0.000198	CbGeAlD
Sunitinib—Nausea—Doxorubicin—thyroid cancer	6.03e-06	0.00013	CcSEcCtD
Sunitinib—RPS6KA3—Signaling Pathways—KRAS—thyroid cancer	4.11e-07	9.26e-06	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—AKT1—thyroid cancer	4.11e-07	9.26e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—KRAS—thyroid cancer	4.08e-07	9.21e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—KRAS—thyroid cancer	4.08e-07	9.21e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—NRAS—thyroid cancer	4.06e-07	9.15e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	4.06e-07	9.15e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—NRAS—thyroid cancer	4.06e-07	9.15e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.05e-07	9.13e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—NRAS—thyroid cancer	4.05e-07	9.12e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PTEN—thyroid cancer	4.04e-07	9.1e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PTEN—thyroid cancer	4.01e-07	9.05e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—BRAF—thyroid cancer	4.01e-07	9.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—BRAF—thyroid cancer	3.99e-07	9e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CCND1—thyroid cancer	3.99e-07	8.99e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PPARG—thyroid cancer	3.97e-07	8.96e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—NRAS—thyroid cancer	3.96e-07	8.92e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PPARG—thyroid cancer	3.94e-07	8.88e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—thyroid cancer	3.93e-07	8.86e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—HRAS—thyroid cancer	3.92e-07	8.83e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—KRAS—thyroid cancer	3.91e-07	8.8e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—NRAS—thyroid cancer	3.9e-07	8.79e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—KRAS—thyroid cancer	3.89e-07	8.76e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—HRAS—thyroid cancer	3.89e-07	8.76e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—NRAS—thyroid cancer	3.88e-07	8.74e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—KRAS—thyroid cancer	3.87e-07	8.74e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—AKT1—thyroid cancer	3.87e-07	8.73e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—KRAS—thyroid cancer	3.86e-07	8.71e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PTEN—thyroid cancer	3.85e-07	8.68e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—AKT1—thyroid cancer	3.84e-07	8.66e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—KRAS—thyroid cancer	3.84e-07	8.65e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PTEN—thyroid cancer	3.84e-07	8.65e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—NRAS—thyroid cancer	3.83e-07	8.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—BRAF—thyroid cancer	3.81e-07	8.6e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CCND1—thyroid cancer	3.78e-07	8.53e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—KRAS—thyroid cancer	3.77e-07	8.5e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—KRAS—thyroid cancer	3.76e-07	8.49e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—HRAS—thyroid cancer	3.76e-07	8.47e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—NRAS—thyroid cancer	3.74e-07	8.42e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—NRAS—thyroid cancer	3.71e-07	8.36e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—HRAS—thyroid cancer	3.69e-07	8.31e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—thyroid cancer	3.68e-07	8.31e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCND1—thyroid cancer	3.67e-07	8.28e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—KRAS—thyroid cancer	3.65e-07	8.24e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—thyroid cancer	3.65e-07	8.23e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PTEN—thyroid cancer	3.65e-07	8.23e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCND1—thyroid cancer	3.63e-07	8.18e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—KRAS—thyroid cancer	3.63e-07	8.18e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—KRAS—thyroid cancer	3.6e-07	8.12e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—NRAS—thyroid cancer	3.6e-07	8.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—NRAS—thyroid cancer	3.58e-07	8.07e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—HRAS—thyroid cancer	3.58e-07	8.07e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—KRAS—thyroid cancer	3.58e-07	8.07e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—KRAS—thyroid cancer	3.57e-07	8.05e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—KRAS—thyroid cancer	3.57e-07	8.04e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCND1—thyroid cancer	3.56e-07	8.03e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCND1—thyroid cancer	3.56e-07	8.03e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PTEN—thyroid cancer	3.54e-07	7.99e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—HRAS—thyroid cancer	3.53e-07	7.97e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HRAS—thyroid cancer	3.52e-07	7.94e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PTEN—thyroid cancer	3.5e-07	7.89e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KRAS—thyroid cancer	3.49e-07	7.88e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	3.49e-07	7.88e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HRAS—thyroid cancer	3.49e-07	7.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—KRAS—thyroid cancer	3.49e-07	7.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KRAS—thyroid cancer	3.48e-07	7.85e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—HRAS—thyroid cancer	3.47e-07	7.82e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—HRAS—thyroid cancer	3.47e-07	7.82e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—AKT1—thyroid cancer	3.46e-07	7.8e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PTEN—thyroid cancer	3.44e-07	7.75e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PTEN—thyroid cancer	3.44e-07	7.75e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—NRAS—thyroid cancer	3.43e-07	7.74e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—AKT1—thyroid cancer	3.43e-07	7.74e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—NRAS—thyroid cancer	3.42e-07	7.72e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KRAS—thyroid cancer	3.4e-07	7.68e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—RXRA—thyroid cancer	3.4e-07	7.67e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCND1—thyroid cancer	3.38e-07	7.62e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCND1—thyroid cancer	3.37e-07	7.6e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—KRAS—thyroid cancer	3.36e-07	7.57e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—thyroid cancer	3.35e-07	7.54e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KRAS—thyroid cancer	3.34e-07	7.53e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TPR—thyroid cancer	3.33e-07	7.51e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—thyroid cancer	3.32e-07	7.48e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—AKT1—thyroid cancer	3.32e-07	7.48e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—thyroid cancer	3.3e-07	7.45e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KRAS—thyroid cancer	3.29e-07	7.43e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—thyroid cancer	3.29e-07	7.43e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—thyroid cancer	3.29e-07	7.41e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.28e-07	7.39e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PTEN—thyroid cancer	3.26e-07	7.36e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—thyroid cancer	3.26e-07	7.36e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NRAS—thyroid cancer	3.26e-07	7.34e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—AKT1—thyroid cancer	3.25e-07	7.34e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PTEN—thyroid cancer	3.25e-07	7.34e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—thyroid cancer	3.22e-07	7.27e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KRAS—thyroid cancer	3.21e-07	7.25e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—thyroid cancer	3.2e-07	7.22e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—thyroid cancer	3.2e-07	7.22e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—thyroid cancer	3.2e-07	7.21e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KRAS—thyroid cancer	3.19e-07	7.19e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NRAS—thyroid cancer	3.16e-07	7.13e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—AKT1—thyroid cancer	3.16e-07	7.12e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—thyroid cancer	3.13e-07	7.05e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NRAS—thyroid cancer	3.12e-07	7.04e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—AKT1—thyroid cancer	3.12e-07	7.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCND1—thyroid cancer	3.11e-07	7.02e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—AKT1—thyroid cancer	3.11e-07	7.02e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—thyroid cancer	3.11e-07	7e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—thyroid cancer	3.11e-07	7e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	3.11e-07	7e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—KRAS—thyroid cancer	3.1e-07	6.99e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—thyroid cancer	3.1e-07	6.98e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—AKT1—thyroid cancer	3.08e-07	6.95e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—thyroid cancer	3.08e-07	6.95e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—thyroid cancer	3.08e-07	6.95e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—thyroid cancer	3.07e-07	6.91e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—thyroid cancer	3.07e-07	6.91e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—thyroid cancer	3.06e-07	6.91e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—thyroid cancer	3.06e-07	6.91e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—thyroid cancer	3.06e-07	6.9e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—thyroid cancer	3.04e-07	6.86e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	3.04e-07	6.85e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—thyroid cancer	3.03e-07	6.84e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—thyroid cancer	3.03e-07	6.84e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—thyroid cancer	3.03e-07	6.82e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PTEN—thyroid cancer	3e-07	6.77e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—thyroid cancer	2.97e-07	6.69e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	2.97e-07	6.69e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—thyroid cancer	2.97e-07	6.69e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—thyroid cancer	2.96e-07	6.67e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—thyroid cancer	2.96e-07	6.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—thyroid cancer	2.95e-07	6.64e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	2.93e-07	6.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—thyroid cancer	2.93e-07	6.61e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—thyroid cancer	2.93e-07	6.6e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—thyroid cancer	2.92e-07	6.58e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—thyroid cancer	2.91e-07	6.57e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—thyroid cancer	2.91e-07	6.56e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—thyroid cancer	2.91e-07	6.56e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—thyroid cancer	2.9e-07	6.55e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—thyroid cancer	2.9e-07	6.54e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—thyroid cancer	2.89e-07	6.52e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—thyroid cancer	2.89e-07	6.51e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—thyroid cancer	2.88e-07	6.49e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—thyroid cancer	2.85e-07	6.43e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—thyroid cancer	2.85e-07	6.42e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—thyroid cancer	2.84e-07	6.4e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—thyroid cancer	2.83e-07	6.38e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—thyroid cancer	2.83e-07	6.37e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—thyroid cancer	2.83e-07	6.37e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—thyroid cancer	2.81e-07	6.34e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—thyroid cancer	2.8e-07	6.32e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—thyroid cancer	2.8e-07	6.31e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—thyroid cancer	2.78e-07	6.27e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—thyroid cancer	2.74e-07	6.18e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—thyroid cancer	2.73e-07	6.16e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—thyroid cancer	2.73e-07	6.15e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—thyroid cancer	2.72e-07	6.14e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—thyroid cancer	2.72e-07	6.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—thyroid cancer	2.71e-07	6.11e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—thyroid cancer	2.7e-07	6.1e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—thyroid cancer	2.7e-07	6.09e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—thyroid cancer	2.69e-07	6.06e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—thyroid cancer	2.69e-07	6.06e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—thyroid cancer	2.69e-07	6.05e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—thyroid cancer	2.68e-07	6.04e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—thyroid cancer	2.68e-07	6.04e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—thyroid cancer	2.68e-07	6.04e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—thyroid cancer	2.64e-07	5.95e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—thyroid cancer	2.64e-07	5.95e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—thyroid cancer	2.63e-07	5.94e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—thyroid cancer	2.63e-07	5.92e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—thyroid cancer	2.62e-07	5.91e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	2.62e-07	5.91e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—thyroid cancer	2.62e-07	5.91e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—thyroid cancer	2.62e-07	5.91e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	2.62e-07	5.9e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—thyroid cancer	2.61e-07	5.89e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—thyroid cancer	2.56e-07	5.76e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—thyroid cancer	2.52e-07	5.68e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—thyroid cancer	2.52e-07	5.68e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—thyroid cancer	2.51e-07	5.66e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—thyroid cancer	2.51e-07	5.65e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—thyroid cancer	2.51e-07	5.65e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—thyroid cancer	2.51e-07	5.65e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—thyroid cancer	2.5e-07	5.64e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—thyroid cancer	2.5e-07	5.63e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.49e-07	5.62e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—thyroid cancer	2.49e-07	5.62e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—thyroid cancer	2.47e-07	5.57e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—thyroid cancer	2.42e-07	5.45e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—thyroid cancer	2.41e-07	5.44e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—thyroid cancer	2.4e-07	5.4e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—thyroid cancer	2.39e-07	5.4e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—thyroid cancer	2.39e-07	5.39e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—thyroid cancer	2.38e-07	5.37e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—thyroid cancer	2.35e-07	5.29e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—thyroid cancer	2.35e-07	5.29e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—thyroid cancer	2.33e-07	5.24e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—thyroid cancer	2.31e-07	5.22e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—thyroid cancer	2.31e-07	5.22e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—thyroid cancer	2.31e-07	5.2e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—thyroid cancer	2.28e-07	5.15e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	2.25e-07	5.08e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—thyroid cancer	2.24e-07	5.06e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—thyroid cancer	2.24e-07	5.06e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	2.24e-07	5.05e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—thyroid cancer	2.23e-07	5.02e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—thyroid cancer	2.22e-07	5.01e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—thyroid cancer	2.22e-07	5e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—thyroid cancer	2.21e-07	4.98e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—thyroid cancer	2.17e-07	4.89e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—thyroid cancer	2.16e-07	4.87e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—thyroid cancer	2.15e-07	4.84e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—thyroid cancer	2.13e-07	4.8e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—thyroid cancer	2.12e-07	4.79e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—thyroid cancer	2.1e-07	4.74e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—RXRA—thyroid cancer	2.1e-07	4.73e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—thyroid cancer	2.06e-07	4.65e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—thyroid cancer	2.05e-07	4.62e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—thyroid cancer	2.04e-07	4.61e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—thyroid cancer	2.02e-07	4.55e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	2e-07	4.51e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—thyroid cancer	1.98e-07	4.47e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—thyroid cancer	1.98e-07	4.47e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—thyroid cancer	1.96e-07	4.42e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—thyroid cancer	1.95e-07	4.4e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—thyroid cancer	1.93e-07	4.35e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—thyroid cancer	1.92e-07	4.32e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	1.91e-07	4.31e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—thyroid cancer	1.88e-07	4.24e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—thyroid cancer	1.88e-07	4.23e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—thyroid cancer	1.84e-07	4.16e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—thyroid cancer	1.83e-07	4.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—thyroid cancer	1.83e-07	4.13e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—thyroid cancer	1.75e-07	3.95e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—thyroid cancer	1.73e-07	3.9e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—thyroid cancer	1.69e-07	3.81e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	1.69e-07	3.81e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—thyroid cancer	1.63e-07	3.67e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—thyroid cancer	1.62e-07	3.65e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—thyroid cancer	1.57e-07	3.54e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—thyroid cancer	1.56e-07	3.51e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—thyroid cancer	1.55e-07	3.49e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—thyroid cancer	1.47e-07	3.32e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—thyroid cancer	1.32e-07	2.98e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—thyroid cancer	1.13e-07	2.54e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.04e-07	2.35e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—thyroid cancer	9.08e-08	2.05e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—thyroid cancer	8.49e-08	1.91e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—thyroid cancer	5.23e-08	1.18e-06	CbGpPWpGaD
